The investigators determined which antibody was best able to specifically bind the fusion protein. They used this antibody to compare the amounts of freestanding BTLA and HVEM and their protein ...

The investigators determined which antibody was best able to specifically bind the fusion protein. They used this antibody to compare the amounts of freestanding BTLA and HVEM and their protein ...

The investigators determined which antibody was best able to specifically bind the fusion protein. They used this antibody to compare the amounts of freestanding BTLA and HVEM and their protein ...

The investigators determined which antibody was best able to specifically bind the fusion protein. They used this antibody to compare the amounts of freestanding BTLA and HVEM and their protein ...

Lipid-tagged antibodies: Bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. Protein Eng. 6, 449–454 ( 1993).

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 ...

a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, as monotherapy for the treatment of unresectable locally advanced or metastatic mucosal or acral melanoma who have not received ...